Effect of age on diagnostic accuracy of mild cognitive impairment definitions for predementia Alzheimer’s disease
| MCI definition | Subjects in group A/B/C/D (n)* | OR | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|
| Values are means (95% confidence intervals) unless stated. | ||||||
| *Group A, subjects eligible for the study who did not meet the criteria of the MCI definition and who had no predementia Alzheimer’s disease; group B, subjects eligible for the study who met criteria of the MCI definition and who had no predementia Alzheimer’s disease; group C, subjects eligible for the study who did not meet criteria of the MCI definition and who had predementia Alzheimer’s disease; group D, subjects eligible for the study who met criteria of the MCI definition and who had predementia Alzheimer’s disease. | ||||||
| ADCS-MIS, Alzheimer’s disease cooperative study-memory impairment study; Gal-Int-11, galantamine international study 11; InDDEx, investigation into delay to diagnosis of Alzheimer’s disease with Exelon; MCI, mild cognitive impairment; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value. | ||||||
| MCI definition of Gal-Int-11 study | ||||||
| Age 50 to 64 years | 47/33/3/6 | 2.8 (0.66 to 12) | 0.67 (0.36 to 0.97) | 0.59 (0.48 to 0.70) | 0.15 (0.04 to 0.27) | 0.94 (0.87 to 1.0) |
| Age 65 to 85 years | 7/11/4/27 | 4.3 (1.0 to 18) | 0.87 (0.75 to 0.99) | 0.39 (0.16 to 0.61) | 0.71 (0.57 to 0.85) | 0.64 (0.35 to 0.92) |
| MCI definition of InDDEx study | ||||||
| Age 55 to 64 years | 32/8/3/5 | 6.9 (1.4 to 35) | 0.63 (0.29 to 0.96) | 0.80 (0.68 to 0.93) | 0.38 (0.12 to 0.65) | 0.92 (0.83 to 1.0) |
| Age 65 to 85 years | 12/6/18/13 | 1.4 (0.43 to 4.9) | 0.42 (0.25 to 0.59) | 0.67 (0.45 to 0.88) | 0.68 (0.48 to 0.89) | 0.40 (0.22 to 0.58) |
| MCI definition of ADCS-MIS study | ||||||
| Age 55 to 64 years | 39/2/3/5 | 33 (4.3 to 244) | 0.63 (0.29 to 0.96) | 0.95 (0.89 to 1.0) | 0.71 (0.38 to 1.0) | 0.93 (0.85 to 1.0) |
| Age 65 to 85 years | 14/4/16/14 | 3.1 (0.82 to 11) | 0.47 (0.29 to 0.65) | 0.78 (0.59 to 0.97) | 0.78 (0.59 to 0.97) | 0.47 (0.29 to 0.65) |
| MCI definition of ampakine study | ||||||
| Age 55 to 64 years | 35/5/3/5 | 12 (2.1 to 65) | 0.63 (0.29 to 0.96) | 0.88 (0.77 to 0.98) | 0.50 (0.19 to 0.81) | 0.92 (0.84 to 1.0) |
| Age 65 to 85 years | 12/5/7/18 | 6.2 (1.6 to 24) | 0.72 (0.54 to 0.90) | 0.71 (0.49 to 0.92) | 0.78 (0.61 to 0.95) | 0.63 (0.41 to 0.85) |
| MCI definition of piracetam study | ||||||
| Age 55 to 64 years | 55/24/4/6 | 4.7 (1.1 to 20) | 0.67 (0.36 to 0.97) | 0.70 (0.60 to 0.80) | 0.20 (0.06 to 0.34) | 0.95 (0.89 to 1.0) |
| Age 65 to 85 years | 10/8/8/23 | 3.6 (1.1 to 12) | 0.74 (0.59 to 0.90) | 0.56 (0.33 to 0.79) | 0.74 (0.59 to 0.90) | 0.56 (0.33 to 0.79) |